Drug intelligence / Profile preview

AX-014

Development stage: Preclinical
Lead developer: Axiom Biosciences
Modality: Vaccines & Immunotherapeutics
Administration: Intralesional

Overview

AX-014 is an AI-designed cancer vaccine currently in preclinical development by Axiom Biosciences. While the majority of Axiom's pipeline (AX-007 through AX-013) is based on mesenchymal stem cell (MSC) platform technology, AX-014 is distinct as a vaccine candidate targeting cancer. The specific antigens or mechanism of the AI-driven design have not been publicly disclosed in detail, but it represents the company's expansion into computational oncology therapeutics.

Beyond the preview

Go deeper on AX-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-014.

Explore the full profile